SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...
Read MoreNotice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...
Read MoreChange of Director's Interest Notice
Appendix 3Y – Change of Director’s Interest Notice, is available to download.
Read MoreLapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...
Read MoreChanges of Director's Interest Notice
Appendix 3Y Change of Director’s Interest Notice Download PDF
Read MoreAppendix 3B
New issue announcement, application for quotation of additional securities and agreement. Download...
Read MoreChanges in Composition to Committeess
CLINUVEL PHARMACEUTICALS LTD today announced changes to the composition of its Audit...
Read MoreCLINUVEL Appoints Non-Executive Director
CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Professor Jeffrey Rosenfeld as...
Read MoreChair’s Address to the Annual General Meeting
Melbourne, Australia, 20 November 2019 A MOMENTOUS ACHIEVEMENT Looking at the year...
Read MoreResults of Meeting
Results of Annual General Meeting In accordance with Listing Rule 3.13.2...
Read MoreManaging Director's AGM Presentation
Melbourne, Australia, 20 November 2019 “We are here today to reflect on...
Read MoreAppendix 4C
CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...
Read MoreTGA Priority Registration Pathway for SCENESSE
CLINUVEL PHARMACEUTICALS LTD today announced that the Australian Therapeutic Goods Administration (TGA)...
Read More